Gilead Sciences Inc (GILD)
75.27
-0.55
(-0.73%)
USD |
NASDAQ |
Sep 21, 16:00
75.28
+0.02
(+0.02%)
After-Hours: 20:00
Gilead Sciences Enterprise Value: 112.30B for Sept. 21, 2023
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 21, 2023 | 112.30B |
| September 20, 2023 | 112.99B |
| September 19, 2023 | 112.93B |
| September 18, 2023 | 112.74B |
| September 15, 2023 | 112.80B |
| September 14, 2023 | 114.91B |
| September 13, 2023 | 114.84B |
| September 12, 2023 | 114.21B |
| September 11, 2023 | 114.51B |
| September 08, 2023 | 113.21B |
| September 07, 2023 | 110.65B |
| September 06, 2023 | 111.02B |
| September 05, 2023 | 112.17B |
| September 01, 2023 | 114.02B |
| August 31, 2023 | 113.81B |
| August 30, 2023 | 115.28B |
| August 29, 2023 | 115.97B |
| August 28, 2023 | 114.51B |
| August 25, 2023 | 114.28B |
| August 24, 2023 | 113.62B |
| August 23, 2023 | 114.51B |
| August 22, 2023 | 113.65B |
| August 21, 2023 | 113.14B |
| August 18, 2023 | 113.06B |
| August 17, 2023 | 113.84B |
| Date | Value |
|---|---|
| August 16, 2023 | 115.70B |
| August 15, 2023 | 117.75B |
| August 14, 2023 | 118.01B |
| August 11, 2023 | 118.20B |
| August 10, 2023 | 118.20B |
| August 09, 2023 | 118.41B |
| August 08, 2023 | 118.30B |
| August 07, 2023 | 119.03B |
| August 04, 2023 | 116.55B |
| August 03, 2023 | 112.63B |
| August 02, 2023 | 112.81B |
| August 01, 2023 | 112.81B |
| July 31, 2023 | 113.39B |
| July 28, 2023 | 114.36B |
| July 27, 2023 | 113.92B |
| July 26, 2023 | 114.77B |
| July 25, 2023 | 114.82B |
| July 24, 2023 | 115.36B |
| July 21, 2023 | 119.07B |
| July 20, 2023 | 118.20B |
| July 19, 2023 | 116.98B |
| July 18, 2023 | 116.06B |
| July 17, 2023 | 115.13B |
| July 14, 2023 | 114.77B |
| July 13, 2023 | 114.17B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
76.35B
Minimum
Dec 30 2020
131.76B
Maximum
Dec 08 2022
99.26B
Average
99.32B
Median
Sep 23 2022
Enterprise Value Benchmarks
| Pfizer Inc | 206.30B |
| Biogen Inc | 37.70B |
| Amgen Inc | 171.40B |
| Regeneron Pharmaceuticals Inc | 82.44B |
| AbbVie Inc | 323.09B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.045B |
| Revenue (Quarterly) | 6.599B |
| Total Expenses (Quarterly) | 4.698B |
| EPS Diluted (Quarterly) | 0.83 |
| Gross Profit Margin (Quarterly) | 78.15% |
| Profit Margin (Quarterly) | 15.84% |
| Earnings Yield | 5.78% |
| Operating Earnings Yield | 13.16% |
| Normalized Earnings Yield | 9.086 |